Thermo Fisher is up about 1 percent today, continuing a steady climb that has pushed the stock up 11 percent over the last month. We think this is mostly normal market movement today, as the stock tracks the broader market higher after a strong run following its recent earnings beat.
Our view
The company is seeing a real recovery in demand as biotechnology spending starts to thaw. If you already own it, there is nothing to do here but sit tight and let the business continue to grow.
Thermo Fisher completes sale of its microbiology business to Astorg
Thermo Fisher has finalized the sale of its microbiology business, which makes tools and supplies used to identify bacteria and other germs. The unit will now operate as an independent company under its new owners, the private equity firm Astorg.
This move helps the company sharpen its focus on higher-growth areas like biopharma research and specialized medicine. While microbiology is a steady business, selling it allows management to put more resources into the complex laboratory equipment and services that drive its core profits.
Expansion plans target 20 percent customer growth in India
Thermo Fisher is aiming to grow its customer base in India by about 15 to 20 percent over the next five years. The plan relies on the country's expanding role in drug research and manufacturing, which creates more demand for the company's lab equipment and supplies. India is becoming a major hub for biopharma, the industry that develops drugs from living organisms. By growing its presence there, Thermo Fisher can capture more of the spending that happens as these companies scale up their production and testing capabilities.
Stifel Nicolaus raised its price target for the company from $600 to $650. This change suggests the firm sees more room for the stock to grow from its current price of about $573. Analysts often adjust these targets when they become more confident in a company's ability to grow its earnings or when the broader industry environment improves.
New diagnostic tools shown at major industry conference
The company showcased its newest diagnostic tools and laboratory solutions at the Association for Diagnostics & Laboratory Medicine conference. These events are a standard way for the company to market its high-end equipment and services to the people who run medical labs. While it shows the company is continuing to refresh its product line, it is a routine part of its sales strategy rather than a major shift in the business.
The company launched a new product called InstaFlux, which is designed to help food microbiology labs prepare testing materials more efficiently. Food testing is a steady, reliable part of the business because labs must constantly check for pathogens to meet safety rules. This new system helps labs process more samples with fewer staff, which is a key selling point for the company's customers who are trying to manage rising costs.
Analysts have recently raised their price targets for Thermo Fisher following the company's sale of its microbiology business. Most analysts, 36 of 43, rate the stock a buy, though the average target of $598 is slightly below today's price.
Average target$597.67-3%vs $614.96 today
Avg price
Low $520High $650
Strong Buy43 analysts
0Bearish
7Neutral
36Bullish
FirmRatingPrice TargetDate
Stifel Nicolaus
Buy
$600→$650
8/5/2026
Piper Sandler
Neutral
$510→$600
7/27/2026
Morgan Stanley
Overweight
$620→$650
7/24/2026
RBC Capital
Sector Perform
$490→$580
7/24/2026
Jefferies
—
$585→$630
7/23/2026
Evercore ISI
Outperform
$575→$570
7/6/2026
Bernstein
Market Perform
$520
6/26/2026
Piper Sandler
Neutral
$510
6/11/2026
HSBC
Hold
$540
6/3/2026
RBC Capital
Sector Perform
$490
5/14/2026
Morgan Stanley
Overweight
$670→$620
4/27/2026
Stifel Nicolaus
Buy
$700→$600
4/24/2026
Thermo Fisher earnings
The company has a perfect record of beating analyst targets over the last two years. Management consistently sets a bar they can clear, which makes their forecasts feel reliable.
Earnings history
EstimateBeatMiss
Thermo Fisher past earnings results
Expected
Actual
Surprise
EPS
$5.72
$6.03
+5.4%
Revenue
$11.71B
$11.99B
+2.5%
Key highlights
Organic growth rebounding: Organic revenue, which excludes the impact of buyouts and currency changes, grew 5% compared to just 1% in the previous quarter. This return to the company's long term target suggests that customer demand is finally strengthening after a period of slower activity.
Profit margins expanding: Adjusted operating margin, a measure of the profit left from every dollar of sales after running the business, rose to 22.8% from 21.9% a year ago. The company is becoming more efficient even as it integrates several new acquisitions into its global operations.
Life sciences recovery: Revenue in the Life Sciences Solutions segment grew 13% to $2.82 billion, a significant jump from the $2.50 billion reported in the same period last year. This division provides the tools and chemicals needed for biological research, and its growth indicates that biotech and pharma customers are increasing their spending again.
Strong cash generation: Free cash flow, the cash left over after paying for operations and equipment, reached $1.68 billion for the quarter compared to $1.11 billion a year ago. This represents 75% of adjusted net income, showing the company is successfully turning its accounting profits into actual cash that can be used to pay down debt or buy back stock.
Shareholder returns and investments: The company spent $1.0 billion to buy back its own shares this quarter and used $8.87 billion for acquisitions during the first half of the year. These moves use the company's cash to grow the business and increase the ownership stake for remaining investors.
Our take: A very strong quarter that signals a turning point for the business. The jump to 5% organic growth proves that the demand slump from biotech customers is fading, which reinforces the long term case for owning the world leader in scientific tools. It is a clean, high quality result.
Thermo Fisher’s next earnings date
Q3 2026
OCT
28
Expectation
EPS
$6.40
Revenue
$11.95B
SEP
15
Dividend payday
Own the stock before this date to get the next dividend payment.
Metrics we are tracking
Metric
Expectations
Status
Organic Revenue Growth
Consistent growth above 5% year-over-year
5% in Q2 2026
Adjusted Operating Margin
Maintaining or expanding margins above 22%
22.8% in Q2 2026
Free Cash Flow Conversion
FCF remaining at or above 90% of adjusted net income